Company profile
Theriva Biologics, Inc.
AMEX: TOVX · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
39DFH 44DQ 29GM —SS 52
v0.1 · 55/100 weight · provisional
↑ listing tenure, Piotroski F · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
$300.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$23.7M
Employees
16
as of 2026-08-22
Market cap
$10.8M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02011
Net income-$23.7M-$23.7M2025
Operating income-$24.1M-$24.1M2025
Total assets$38.2M$38.2M2025
Liabilities$22.9M$22.9M2025
Equity$15.4M$15.4M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Theriva Biologics, Inc.’s revenue?
Theriva Biologics, Inc. booked $0 in FY2011 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Quoin Pharmaceuticals, Ltd.37DHemostemix Inc——Integrated Cannabis Solutions, Inc.——Lunai Bioworks Inc.20DGT Biopharma, Inc.32DPreveCeutical Medical Inc.——Neighbors
Montgomery →Key facts
CEOSteven A. Shallcross
SectorHealthcare
IndustryBiotechnology
HeadquartersRockville, MD
ExchangeAMEX: TOVX
Employees16
IPO date2006-12-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.